Опыт использования препарата селеназа в комплексном лечении гнойно-воспалительных заболеваний органов малого таза осложненный перитонитом

Abstract

An analysis of the results of treatment of 48 patients with acute purulent and inflammatory disease of the small pelvis organs with endolymphatic introduction of the Selenase is presented. The age of the patients was from 20 to 45 years. Course of treatment was 5-10 days. The use of the Selenase in the scheme of intensive therapy facilitated substantial positive dynamics of clinical status. A distinct reduction of paresis of the gastrointestinal tract and decrease phenomena endotoxemia were observed clinically in most cases (94,2±2,1%). In laboratory indicators after 5-10 daily courses of intensive therapy with use of the Selenase, a tendency to normalization of the blood formula and reduce the number of leukocytes, the increase in 2 times the number of lymphocytes were noted. The use of CRT was neutralized antioxidant and immunological imbalance, increased phagocytic activity. Endolymphatic introduction of preparation contributed cleansing of wounds and cavities, regress of purulent and inflammatory processes. Application of the Selenase is significantly important factor in improving the prediction of treatment patients with purulent and inflammatory disease of the organs of small pelvis. Results of this research can be the basis for further research to develop new approaches in the field of endolymphatic therapy. Complications and cases of mortality from endolymphatic therapy by the Selenase didn´t revealed.